Victoire de Margerie welcomes you to Rondol
“We created Rondol Industrie in Eastern France in June 2012 as a research group with the objective both to miniaturize hot melt extrusion (HME) equipment and to develop machines fitted to Pharma and Biotech standards.
HME technology is well known by the food industry and widely used for producing and shaping many materials but it has only been of interest for the pharmaceutical industry to embed drugs into polymers since 2000 and following academic surveys by Breitenbach, Mc Ginnity, Repka and Andrews that demonstrated high quality of HME processing and improved solubility for complex APIs such as Kaletra.
The extraordinary precision of dispersion offered by HME even at the micro scale indeed allows the production of very small tablets that will always have the same percentage of API included - and this with lower production costs due to a reduction in number of production steps. Also the drug efficiency will be higher and the patient comfort increased as the patient will absorb a daily dose at home instead of facing a heavy diffusion session every two weeks at the hospital - and this with lower costs for healthcare insurance systems due to a reduced number of hospital beds/days. And big Pharmas could use this new drug delivery solution to get a patent extension for some drugs that have been extremely expensive to develop – a good idea to fight the famous patent cliff effect.
Since 2012 we have redesigned machine parts, incorporated temperature control on all process (for fragile materials with narrow range from melting to degradation), simplified the cleaning system in between lots, and made the machine « vertical » (to divide by 5 its footprint and cope with white room capital intensity per m2). The result is a patented machine "All in One" (with easy plug in/out of ancillary devices) that we prototyped at Paris School of Physics in 2015, installed as an industrial first at Gatefossé US early 2017 and launched at AAPS in San Diego last November.
In parallel to our initial objective on Pharma and Biotech applications, our customer focus has allowed us to discover or further develop other applications for HME at the microscale: high temperature polymers (Arkema, France), zips copping with extreme temperature conditions (YKK, UK and Canada), cable joint moulder system (Nexans, Norway), 3D Printing filament (Greenwich University, UK) and powder compounds for other 3D technologies (Lorraine University, France) .
Our plan for 2018 is to expand our technical and maintenance support from EU based to both EU and North America based and to continue to develop and implement improvements to our machines as the industry makes suggestions for improvements.”
Victoire de Margerie, CEO